Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways

BJU International - Tập 104 Số 4 - Trang 438-448 - 2009
André N. Vis1, Fritz H. Schröder1
1Departments of Urology, VU Medical Centre, Amsterdam, and Erasmus Medical Centre, Rotterdam, the Netherlands

Tóm tắt

OBJECTIVEKnowledge of the molecular and cellular changes that occur during the transition of hormone‐naïve to castration‐resistant prostate cancer (CRPC) is increasing rapidly. This might provide a window of opportunity for (future) drug development, and for treating patients with these potential devastating states of disease. The objective of this review is to provide an understanding of the mechanisms that prostate cancer cells use to bypass androgen‐deprived conditions.METHODSWe searched PubMed for experimental and clinical studies that describe the molecular changes that lead to CRPC.RESULTSCRPC remains dependent on a functional androgen receptor (AR), AR‐mediated processes, and on the availability of intraprostatic intracellular androgens. CRPCs might acquire different (molecular) mechanisms that enable them to use intracellular androgens more efficiently (AR amplification, AR protein overexpression, AR hypersensitivity), use alternative splice variants of the AR protein to mediate androgen‐independent AR functioning, and have altered co‐activator and co‐repressor gene and protein expression. Furthermore, CRPCs might have the ability to synthesise androgens de novo from available precursors through a renewed and up‐regulated synthesis of steroid‐hormone converting enzymes. Blocking of enzymes key to de novo androgen synthesis could be an alternative means to treat patients with advanced and/or metastatic disease.CONCLUSIONIn CRPC, prostate cancer cells still rely on intracellular androgens and on an active AR for growth and survival. CRPCs have gained mechanisms that enable them to use steroids from the circulation more efficiently through altered gene expression, and through a renewed and up‐regulated synthesis of steroid hormone‐converting enzymes. Additionally, CRPCs might synthesise AR isoforms that enable AR mediated processes independent from available androgens.

Từ khóa


Tài liệu tham khảo

10.1016/j.eururo.2007.10.047

Bruchovsky N, 1968, The conversion of testosterone to 5‐alpha‐androstan‐17‐beta‐ol‐3‐one by rat prostate in vivo and in vitro, J Biol Chem, 243, 2012, 10.1016/S0021-9258(18)93542-8

10.1210/jc.2006-0968

10.1016/S0025-6196(19)30649-4

10.1126/science.3353727

10.1200/JCO.2002.10.018

Quarmby VE, 1990, Expression and localization of androgen receptor in the R‐3327 Dunning rat prostatic adenocarcinoma, Cancer Res, 50, 735

10.1210/jc.2002-022038

10.1111/j.1464-410X.2005.05527.x

10.1126/science.3283939

Colombel M, 1992, Hormone‐regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle, Cancer Res, 52, 4313

10.1210/endo-122-2-552

10.1210/edrv-8-3-338

10.1677/erc.0.0090061

10.1002/(SICI)1097-0045(1996)6 <22::AID-PROS5>3.0.CO;2-M

Gao J, 2001, Conversion from a paracrine to an autocrine mechanism of androgen‐stimulated growth during maligant transformation of prostate epithelial cells, Cancer Res, 61, 5038

10.1158/0008-5472.CAN-07-5997

10.1158/0008-5472.CAN-05-4000

10.1158/0008-5472.CAN-08-0249

10.1002/jcb.10724

Borner MM, 1995, Drug‐induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53‐negative human prostate cancer cell line PC‐3, Cancer Res, 55, 2122

10.1093/carcin/24.3.453

10.1016/0140-6736(91)93208-Q

10.1093/aje/kwi203

10.1093/jnci/djm286

10.1200/JCO.2004.02.027

10.1002/ijc.23715

10.1038/nrc1751

Huggins C, 1941, Studies on prostate cancer. 1 The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, 293

10.1001/archsurg.1941.01210140043004

Huggins C, 1967, Endocrine‐induced regression of cancers, Cancer Res, 27, 1925

10.1016/0090-4295(89)90106-4

10.1016/0090-4295(91)80077-K

10.1016/j.eururo.2007.09.002

10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A

10.7326/0003-4819-132-7-200004040-00009

10.1056/NEJM198411153112004

10.1111/j.1464-410X.1992.tb15865.x

10.1056/NEJM199810083391504

10.1056/NEJMoa040720

10.1200/JCO.1989.7.5.590

10.1002/1097-0142(19930201)71:3 <1068::AID-CNCR2820711427>3.0.CO;2-5

10.1016/S0022-5347(01)64924-3

10.1016/S1078-1439(00)00123-X

10.1016/S0140-6736(95)92163-X

10.1056/NEJM198908173210702

10.1016/0090-4295(93)90634-M

10.1200/JCO.2007.15.9749

Solit DB, 2002, 17‐Allylamino‐17‐demethoxygeldanamycin induces the degradation of androgen receptor and HER‐2/neu and inhibits the growth of prostate cancer xenografts, Clin Cancer Res, 8, 986

10.1158/0008-5472.CAN-07-2057

10.1038/sj.cgt.7700416

10.1158/1535-7163.MCT-04-0313

Zegarra‐Morro OL, 2002, Disruption of androgen receptor function inhibits proliferation of androgen‐refractory prostate cancer cells, Cancer Res, 62, 1008

10.1016/S0022-5347(05)66935-2

10.1158/0008-5472.CAN-06-3332

10.1158/0008-5472.CAN-2148-2

10.1038/35094009

10.1016/S0090-4295(02)01593-5

Koivisto P, 1997, Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer, Cancer Res, 57, 314

10.1038/ng0495-401

10.1056/NEJM199505253322101

Taplin ME, 2003, Androgen receptor mutations in androgen‐independent prostate cancer: cancer and leukemia group B study 9663, Cancer Res, 21, 2673

Van Der Kwast ThH, 1991, Androgen receptors in endocrine‐therapy‐resistant human prostate cancer, Int J Med, 48, 189

Linja MJ, 2001, Amplication and overexpression of androgen receptor gene in hormone‐refractory prostate cancer, Cancer Res, 3, 550

Bubendorf L, 1999, Survey of gene amplifications during prostate cancer progression by high‐throughput fluorescence in situ hybridization on tissue microarray, Cancer Res, 59, 803

10.1016/S0002-9440(10)63112-4

Gregory CW, 2001, A mechanism for androgen receptor‐mediated prostate cancer recurrence after androgen deprivation therapy, Cancer Res, 61, 4315

Bruchovsky N, 2000, Intermittent androgen suppression for prostate cancer. Canadian Prospective Trial and related observations, Mol Urol, 4, 191

Ruizeveld de Winter JA, 1994, Androgen receptor status in localized and progressive hormone refractory human prostate cancer, Am J Pathol, 144, 735

Gregory CW, 2001, Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen, Cancer Res, 61, 2892

10.1210/edrv-7-1-67

10.1016/0960-0760(92)90010-G

10.1073/pnas.89.14.6319

10.1002/pros.2990220103

Marcelli M, 2000, Androgen receptor mutations in prostate cancer, Cancer Res, 60, 944

Buchanan G, 2001, Collocation of androgen receptor gene mutations in prostate cancer, Clin Cancer Res, 7, 1273

10.1200/JCO.2003.11.102

Koivisto P, 1998, Androgen receptor gene and hormonal therapy failure of prostate cancer, Am J Pathol, 152, 1

Fenton MA, 1997, Functional characterization of mutant androgen receptors from androgen‐independent prostate cancer, Clin Cancer Res, 3, 1383

10.1038/sj.bjc.6690684

10.1200/JCO.1993.11.8.1566

10.1038/71560

10.1159/000052292

10.1007/BF00941991

Culig Z, 1994, Androgen receptor activation in prostatic tumor cell lines by insulin‐like growth factor‐I, keratinocyte growth factor, and epidermal growth factor, Cancer Res, 54, 5474

10.1158/0008-5472.CAN-08-0594

10.1158/0008-5472.CAN-08-2764

10.1158/0008-5472.CAN-08-3795

10.1158/0008-5472.CAN-03-3998

10.1158/0008-5472.CAN-05-1840

10.1093/jnci/93.22.1687

10.1074/jbc.274.13.8570

10.1016/j.steroids.2007.01.004

10.1016/j.urology.2008.03.033

10.1001/jama.296.19.2351

10.1158/1078-0432.CCR-05-0525

10.1158/0008-5472.CAN-06-1593

10.1210/jcem-71-6-1552

10.1158/1078-0432.CCR-04-0913

10.1158/1078-0432.CCR-1146-03

10.1677/erc.1.01048

Geller J, 1985, Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer, Semin Oncol, 12, 28

10.1158/0008-5472.CAN-03-0130

10.1016/S0094-0143(05)70066-5

Craft N, 1999, Evidence for clonal outgrowth of androgen‐independent prostate cancer cells from androgen‐dependent tumors through a two‐step process, Cancer Res, 59, 5030

10.1074/jbc.275.2.1216

10.1016/S0092-8674(00)81780-8

Nesslinger NJ, 2003, Androgen‐independent growth of LNCaP prostate cancer cells is mediated by gain‐of‐function mutant p53, Cancer Res, 63, 2228

10.1038/6495

10.1074/jbc.M203313200

Hobisch A, 1998, Interleukin‐6 regulates prostate‐specific protein expression in prostate carcinoma cells by activation of the androgen receptor, Cancer Res, 58, 4640

Colombel M, 1993, Detection of the apoptosis‐suppressing oncoprotein bc1–2 in hormone‐refractory human prostate cancers, Am J Pathol, 143, 390

Furuya Y, 1996, Expression of bcl‐2 and the progression of human and rodent prostatic cancers, Clin Cancer Res, 2, 389

10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H

Thông tin
Thông tin xuất bản

BJU International

Tập 104 Số 4

438-448

Thông tin tác giả